Oral semaglutide is on its way.
News & Analysis: Novo Nordisk
NVO earnings call for the period ending March 31, 2019.
The full year may be a different story.
NVO earnings call for the period ending December 31, 2018.
Diabetes and related conditions affect over 100 million Americans and many more worldwide. Here are three companies helping fight that disease.
Experimental new drugs at critical stages of development could soon send these stocks screaming in one direction or another.
Growth on one hand, but declines on the other.
NVO earnings call for the period ending September 30, 2018.
Want to put money to work in this $825 billion market? Here's what you need to know.
Payers continue to seek lower drug prices from the diabetes expert.